NASDAQ:BEAM Beam Therapeutics (BEAM) Stock Price, News & Analysis $24.96 +0.03 (+0.14%) As of 02:56 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Beam Therapeutics Stock (NASDAQ:BEAM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Beam Therapeutics alerts:Sign Up Key Stats Today's Range$24.50▼$25.2050-Day Range$23.10▼$31.0352-Week Range$20.23▼$38.26Volume595,468 shsAverage Volume2.03 million shsMarket Capitalization$2.58 billionP/E RatioN/ADividend YieldN/APrice Target$50.10Consensus RatingModerate Buy Company Overview Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines for patients with serious diseases. The company’s platform uses base editing, a form of gene editing designed to make targeted changes to individual DNA letters without creating double-strand breaks. Beam is also advancing related editing technologies and delivery systems intended to improve the precision and effectiveness of genetic treatments. Beam’s pipeline includes investigational programs for diseases such as sickle cell disease, beta thalassemia, alpha-1 antitrypsin deficiency and glycogen storage disease type Ia. Its lead program, BEAM-101, is an ex vivo cell therapy intended to treat sickle cell disease and beta thalassemia by editing a patient’s blood stem cells before they are returned to the body. Other programs are designed to use in vivo editing, in which the editing treatment is delivered directly to the patient. Founded in 2017 and headquartered in Cambridge, Massachusetts, Beam has established collaborations with pharmaceutical and biotechnology companies to develop and commercialize genetic medicines. The company’s research and development activities support potential treatments for patients in the United States and international markets. John Evans serves as Beam Therapeutics’ chief executive officer. Its therapies remain investigational and are subject to clinical development and regulatory review.AI Generated. May Contain Errors. Read More Beam Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreBEAM MarketRank™: 2.17781619896 of 5 starsBeam Therapeutics scored higher than 44% of companies evaluated by MarketBeat, and ranked 559th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingBeam Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 8 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialBeam Therapeutics has a consensus price target of $50.10, representing about 100.3% upside from its current price of $25.02.Amount of Analyst CoverageBeam Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Beam Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Beam Therapeutics are expected to decrease in the coming year, from ($4.49) to ($5.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Beam Therapeutics is -28.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Beam Therapeutics is -28.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBeam Therapeutics has a P/B Ratio of 2.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Beam Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted27.73% of the float of Beam Therapeutics has been sold short.Short Interest Ratio / Days to CoverBeam Therapeutics has a short interest ratio ("days to cover") of 15.3, which indicates bearish sentiment.Change versus previous monthShort interest in Beam Therapeutics has recently increased by 6.43%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldBeam Therapeutics does not currently pay a dividend.Dividend GrowthBeam Therapeutics does not have a long track record of dividend growth.Read more about Beam Therapeutics' dividend. News and Social Media2.7 / 5News Sentiment0.29 News SentimentBeam Therapeutics has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Beam Therapeutics this week, compared to 6 articles on an average week.Search InterestOnly 10 people have searched for BEAM on MarketBeat in the last 30 days. This is a decrease of -9% compared to the previous 30 days.MarketBeat Follows12 people have added Beam Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 140% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Beam Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,018,259.00 in company stock.Percentage Held by Insiders3.80% of the stock of Beam Therapeutics is held by insiders.Percentage Held by Institutions99.68% of the stock of Beam Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Beam Therapeutics' insider trading history. Receive BEAM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Beam Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BEAM Stock News HeadlinesBeam Therapeutics (NASDAQ: BEAM) CEO sells 50,000 shares after option exerciseOctober 20 at 4:03 AM | americanbankingnews.comBeam Therapeutics Insider Sold Shares Worth $1,188,745, According to a Recent SEC FilingOctober 19 at 9:05 AM | marketscreener.comMReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.October 21 at 1:00 AM | Base Camp Trading (Ad)Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?October 17, 2026 | fool.comBeam Therapeutics (NASDAQ:BEAM) CEO John Evans Sells 25,000 Shares of Company StockOctober 17, 2026 | insidertrades.comHC Wainwright Reaffirms Buy Rating for Beam Therapeutics (NASDAQ:BEAM)October 17, 2026 | americanbankingnews.comBeam Therapeutics (NASDAQ:BEAM) Earns "Outperform" Rating from WedbushOctober 16, 2026 | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAMOctober 15, 2026 | prnewswire.comSee More Headlines BEAM Stock Analysis - Frequently Asked Questions How have BEAM shares performed this year? Beam Therapeutics' stock was trading at $27.72 at the beginning of 2026. Since then, BEAM shares have decreased by 9.7% and is now trading at $25.0180. How were Beam Therapeutics' earnings last quarter? Beam Therapeutics Inc. (NASDAQ:BEAM) posted its quarterly earnings results on Tuesday, August, 4th. The company reported ($1.18) EPS for the quarter, missing the consensus estimate of ($1.11) by $0.07. The firm's revenue for the quarter was down 94.2% on a year-over-year basis. Does Beam Therapeutics have any subsidiaries? The following companies are subsidiaries of Beam Therapeutics: Blink Therapeutics Inc.. When did Beam Therapeutics IPO? Beam Therapeutics (BEAM) raised $169 million in an initial public offering (IPO) on Thursday, February 6th 2020. The company issued 10,588,236 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Barclays acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Beam Therapeutics' major shareholders? Top institutional investors of Beam Therapeutics include Vontobel Holding Ltd. (0.02%), SteelPeak Wealth LLC (0.02%), Nisa Investment Advisors LLC and Versant Capital Management Inc. Insiders that own company stock include John M Evans, Fmr Llc, Giuseppe Ciaramella, Christine Bellon, Amy Simon, Terry-Ann Burrell and Bethany J Cavanagh. View institutional ownership trends. How do I buy shares of Beam Therapeutics? Shares of BEAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Beam Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Beam Therapeutics investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Advanced Micro Devices (AMD), Palantir Technologies (PLTR), Tesla (TSLA), Intellia Therapeutics (NTLA) and Taiwan Semiconductor Manufacturing (TSM). Company Calendar Last Earnings8/04/2026Today10/21/2026Study result10/27/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 BEAM's financial health is in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BEAM CIK1745999 Webwww.beamtx.com Phone857-327-8775FaxN/AEmployees540Year Founded2017Price Target and Rating Average Price Target for Beam Therapeutics$50.10 High Price Target$80.00 Low Price Target$26.00 Potential Upside/Downside+100.9%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($0.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$79.99 million Net Margins-54.75% Pretax Margin-55.45% Return on Equity-30.71% Return on Assets-24.07% Debt Debt-to-Equity Ratio0.09 Current Ratio14.57 Quick Ratio14.57 Sales & Book Value Annual Sales$156.04 million Price / Sales16.51 Cash FlowN/A Price / Cash FlowN/A Book Value$12.20 per share Price / Book2.04Miscellaneous Outstanding Shares103,288,000Free Float99,363,000Market Cap$2.58 billion OptionableOptionable Beta2.20 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:BEAM) was last updated on 10/21/2026 by MarketBeat.com Staff. From Our PartnersTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beam Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Beam Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
